Genmab AS (GMAB) — Capital Reinvestment Ratio
Genmab AS (GMAB) has a Capital Reinvestment Ratio of 0.04x as of December 2025, meaning it reinvests 0% of its operating cash flow ($300.34 Million) in capital expenditures ($12.99 Million). Check tangible equity quality of Genmab AS to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Genmab AS Capital Reinvestment Ratio (2007–2025)
This chart tracks Genmab AS's Capital Reinvestment Ratio across 15 annual periods. For the full cash flow conversion analysis, see Genmab AS cash conversion from operations.
Annual Capital Reinvestment Ratio for Genmab AS (2007–2025)
Year-by-year Capital Reinvestment Ratio for Genmab AS from 2007 to 2025. See free cash flow generation of Genmab AS to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.03x | $1.19 Billion | $37.03 Million | ▲ +29.6% |
| 2024 | 0.02x | $7.77 Billion | $187.00 Million | ▼ -52.8% |
| 2023 | 0.05x | $7.38 Billion | $376.00 Million | ▼ -37.1% |
| 2022 | 0.08x | $3.91 Billion | $317.00 Million | ▼ -28.4% |
| 2021 | 0.11x | $2.23 Billion | $252.00 Million | ▲ +137.0% |
| 2020 | 0.05x | $6.43 Billion | $307.00 Million | ▼ -43.0% |
| 2019 | 0.08x | $1.33 Billion | $111.00 Million | ▼ -82.2% |
| 2018 | 0.47x | $1.01 Billion | $477.37 Million | ▲ +744.5% |
| 2017 | 0.06x | $1.59 Billion | $88.51 Million | ▼ -44.9% |
| 2016 | 0.10x | $327.72 Million | $33.11 Million | ▼ -76.8% |
| 2015 | 0.43x | $311.45 Million | $135.39 Million | ▼ -23.6% |
| 2014 | 0.57x | $132.67 Million | $75.44 Million | ▲ +348.2% |
| 2012 | 0.13x | $70.92 Million | $9.00 Million | ▲ +236.5% |
| 2010 | 0.04x | $268.17 Million | $10.11 Million | ▲ +48.5% |
| 2007 | 0.03x | $505.90 Million | $12.84 Million | — |